| 今开：0.0 | 昨收：19.75 |
| 最高：0.0 | 最低：0.0 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：3.84691448E8 |
智通财经APP获悉，强生(JNJ.US)旗下杨森(Janssen)公司5月3日宣布与Cellular Biomedicine Group(CBMG，西比曼生物科技集团)达成全球合作和许可协议，以开发、生产和商业化下一代嵌合抗原受体T细胞(CAR-T)疗法，用于治疗B细胞恶性肿瘤。 ... 网页链接
2023年04月03日 10:22:19 4月3日，专注于开发创新细胞疗法的生物制药公司西比曼生物科技（Cellular Biomedicine Group,CBMG）今日正式宣布，启动公司旗下异体人源脂肪间充质祖细胞注射液AlloJoin®的III期临床试验。... 网页链接
$Cellular Biomedicine(CBMG)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-21-000731 Act: 33 Size: 1 KB 网页链接
$Cellular Biomedicine(CBMG)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-21-000732 Act: 33 Size: 1 KB 网页链接
$Cellular Biomedicine(CBMG)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-21-000733 Act: 33 Size: 1 KB 网页链接
$Cellular Biomedicine(CBMG)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-21-000730 Act: 33 Size: 1 KB 网页链接
$Cellular Biomedicine(CBMG)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-21-026984 Act: 34 Size: 77 KB 网页链接
$Cellular Biomedicine(CBMG)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001185185-21-000254 Act: 34 Size: 51 KB 网页链接
$Cellular Biomedicine(CBMG)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-21-000249 Act: 34 Size: 3 KB 网页链接
$Cellular Biomedicine(CBMG)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0000902664-21-001527 Act: 34 Size: 237 KB 网页链接
$Cellular Biomedicine(CBMG)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001654954-21-001896 Act: 33 Size: 36 KB 网页链接
$Cellular Biomedicine(CBMG)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001654954-21-001897 Act: 33 Size: 38 KB 网页链接